Document:

Exhibit 10.3

 

EXECUTIVE TRANSITION AND SEPARATION AGREEMENT

 

This Executive Transition
and Separation Agreement (this “Agreement”), is entered into as of the date set forth on the signature page below (the
 “Execution Date”), by and between Dr. Orsula V. Knowlton (“you”) and Tabula Rasa Healthcare, Inc.
(together with its wholly owned subsidiaries and affiliates, the “Company”).

 

BACKGROUND

 

WHEREAS, you currently serve
as President and Chief New Business & Marketing Officer of the Company (“President”);

 

WHEREAS, you and the Company
are parties to that certain Change-In-Control and Severance Agreement, effective January 1, 2018 (the “Severance Agreement”),
which will terminate in its entirety upon execution of this Agreement;

 

WHEREAS, you are resigning
from the Board of Directors of the Company (the “Board”) effective as of the Execution Date and the execution of this
Agreement shall constitute such resignation (the “Resignation Date”);

 

WHEREAS, you and the Company
have mutually agreed that your employment with the Company will end on the Execution Date (the “Termination Date”)
and you have agreed to enter into a consulting agreement with the Company pursuant to which the Company will engage you as an independent
contractor to provide certain advisory and transition services from the Termination Date through December 31, 2022 as set forth in such
consulting agreement, substantially in the form attached hereto as Exhibit A (the “Consulting Agreement”);

 

WHEREAS, both you and the
Company desire to enter into this Agreement to set forth the terms and conditions of the termination of your employment with the Company,
including your agreement to provide certain advisory and transition services through December 31, 2022 pursuant to the Consulting Agreement
and the severance payable to you upon the Termination Date.

 

NOW THEREFORE, in consideration
of the mutual promises set forth in this Agreement and of other good and valuable consideration, the sufficiency of which you acknowledge,
and intending to be legally bound hereby, you and the Company agree as follows:

 

1.           Recitals.
The foregoing recitals are hereby made part of this Agreement and are incorporated herein by reference.

 

2.         
General Terms of Separation. Regardless of whether you sign this Agreement, the Company will provide you with (a) any $463,500
(“Base Salary”) earned through the Termination Date that remains unpaid; (b) any accrued but unused personal time
off days; (c) reimbursement for any outstanding expenses for which you have not been reimbursed and which are authorized and (d)
any vested benefits under the Company’s employee benefit plans in accordance with the terms of such plans, as accrued through the
Termination Date (collectively, the “Accrued Obligations”). The Accrued Obligations, which are set forth on Schedule
A, shall be paid following the Termination Date at such times and in accordance with such plans and policies as would normally apply to
such amounts or benefits.

 

     

     

    

 

3.         
Consideration. If you (a) sign and do not revoke this Agreement (b) comply with the obligations set forth in this Agreement
and (c) continue to comply with the restrictive covenants in Paragraph 7 below, then the Company will provide you with the following severance
payments and benefits (collectively, the “Consideration”):

 

(i)           You
will receive continuation of your Base Salary in accordance with the Company’s regular payroll practices, less all relevant taxes
and other withholdings, for a period of eighteen (18) months starting on the first payroll date following the Termination Date.

 

(ii)         
For the eighteen (18) months following the Termination Date (the “Coverage Period”), if you timely and properly
elect to receive continued health coverage under the Company’s health plan under the Consolidated Omnibus Budget Reconciliation
Act (“COBRA”), you will receive continued health (including hospitalization, medical, dental, vision, etc.) insurance
coverage (“COBRA Coverage”) that is substantially similar in all material respects to the coverage provided to other
Company employees as of the Termination Date, provided that you pay to the Company, on a monthly basis, an amount equal to the amount
active Company employees pay for such coverage. You agree to promptly notify the Company of your coverage under an alternative health
plan upon becoming covered by such alternative plan, at which time your COBRA Coverage may be reduced or eliminated, as applicable, to
the extent that continued receipt of COBRA Coverage would result in duplicative benefits. The COBRA continuation coverage period under
Section 4980B of the Internal Revenue Code of 1986, as amended (the “Code”) shall run concurrently with the Coverage
Period.

 

(iii)       
You will receive reimbursement for reasonable fees and costs you incur for outplacement services during the twelve (12) months
following the Termination Date, up to a maximum of $25,000, provided that you submit any requests for reimbursement to the Company within
thirty (30) days of the date the expense is incurred.

 

(iv)       
 301,542 unvested shares of restricted stock you hold pursuant to the Company’s 2016 Omnibus Incentive Compensation Plan
will vest as of the Termination Date. All other restricted stock awards, including all performance stock unit awards you hold in the Company
that are unvested as of the Termination Date will be terminated and cancelled as of the Termination Date.

 

You agree and acknowledge
that the payments described in Section 2 are the final compensation to which you are entitled and you are not owed any other money or
compensation for services performed. You will not be eligible for the Consideration described in this Paragraph 3 unless the Company
has received an executed copy of this Agreement, which has not been revoked. You further agree that the amounts described in Section 3
are the full consideration for this Agreement and are equal to or exceed the severance benefits described in the Severance Agreement and
are equal to or exceed any benefits, compensation, or other financial consideration to which Employee would be entitled absent his signing
of this Agreement.

 

4.         
General Release.

 

(a)        
In exchange for the consideration and other conditions set forth in this Agreement, you hereby generally and completely release
the Company, each of their affiliated entities, and their respective current and former directors, officers, employees, shareholders,
stockholders, partners, general partners, limited partners, managers, members, managing directors, operating affiliates, agents, attorneys,
predecessors, successors, Company and subsidiary entities, insurers, assigns and affiliated entities (collectively, the “Released
Parties”) of and from any and all claims, liabilities and obligations, both known and unknown, arising from or related to events,
acts, or omissions occurring prior to or on the date you sign this Agreement (collectively, the “Released Claims”).
The Released Claims include, but are not limited to: (a) all claims arising from or in any way related to your employment or other
participation in connection with any of the Released Parties, or the termination of that employment or participation; (b) all claims
related to compensation or benefits, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, change-in-control
payments, fringe benefits, or profit sharing or any claims under the Severance Agreement; (c) all claims for breach of contract,
wrongful termination, and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for
fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal, state, and local statutory claims,
including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights
Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967
(as amended) (the “ADEA”), the Employee Retirement Income Security Act of 1974 (“ERISA”) (including,
but not limited to, claims for breach of fiduciary duty under ERISA), and the Older Workers Benefit Protection Act (the “OWBPA”).
In giving the releases set forth above, which include claims which may be unknown to you at present, you hereby expressly waive and relinquish
all rights and benefits under any law or legal principle in any jurisdiction with respect to your release of claims herein, including
but not limited to the release of unknown and unsuspected claims. Notwithstanding anything to the contrary in this Paragraph 4, you are
not prohibited from making or asserting and you are not waiving: (i) your rights under this Agreement; (ii) any claims for unemployment
compensation, workers’ compensation or state disability insurance benefits pursuant to the terms of applicable state laws; (iii)
any claim for vested benefits under any Company-sponsored retirement or welfare benefit plan; (iv) any other right that may not be released
under applicable law; and (v) your rights, if any, to indemnification pursuant to the Company’s organizational documents or any
D&O insurance policy.

 

    2

     

    

 

(b)        
In exchange for the conditions set forth in this Agreement, the Company hereby generally and completely releases you of and from
any and all claims, liabilities and obligations, both known and unknown, in law or in equity, by contract, or otherwise, arising from
or related to events, acts, or omissions occurring prior to or on the date you sign this Agreement, in each case, solely related to the
pledges and subsequent forced sales of the Company’s securities sold by you and your spouse in November 2021.

 

5.         
Reports to Government Entities. Nothing in this Agreement restricts or prohibits you from initiating communications directly
with, responding to any inquiries from, providing testimony before, providing confidential information to, reporting possible violations
of law or regulation to, or from filing a claim or assisting with an investigation directly with a self-regulatory authority or a government
agency or entity, including the U.S. Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board,
the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General (collectively, the “Regulators”),
or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation. However,
to the maximum extent permitted by law, you are waiving your right to receive any individual monetary relief from the Company, or any
others covered by the Released Claims resulting from such claims or conduct, regardless of whether you or another party has filed them,
and in the event you obtain such monetary relief the Company will be entitled to an offset for the payments made pursuant to this Agreement.
This Agreement does not limit your right to receive an award from any Regulator that provides awards for providing information relating
to a potential violation of law. You do not need the prior authorization of the Company to engage in conduct protected by this paragraph,
and you do not need to notify the Company that you have engaged in such conduct. Please take notice that federal law provides criminal
and civil immunity to federal and state claims for trade secret misappropriation to individuals who disclose a trade secret to their attorney,
a court, or a government official in certain, confidential circumstances that are set forth at 18 U.S.C. §§ 1833(b)(1) and 1833(b)(2),
related to the reporting or investigation of a suspected violation of the law, or in connection with a lawsuit for retaliation for reporting
a suspected violation of the law. Pursuant to the Defend Trade Secrets Act of 2016, you will not be held criminally or civilly liable
under any federal or state trade secret law for the disclosure of the trade secrets of the Company or any of its affiliates that is made
by you (a) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely
for the purpose of reporting or investigating a suspected violation of law, or (b) in a complaint or other document filed in a lawsuit
or other proceeding, if such filing is made under seal.

 

    3

     

    

 

6.         
No Actions Pending Against the Company. You acknowledge and agree that that: (a) you are not aware of any facts that may
constitute violations of the Company’s policies and/or legal obligations; and (b) you have not filed any discrimination, wrongful
discharge, wage and hour, or any other complaints or charges against the Released Parties in any local, state or federal court, tribunal,
or administrative agency.

 

7.         
Restrictive Covenants. You expressly acknowledge that a condition your receipt of the Consideration set forth in Paragraph
3 is your continued compliance with the restrictive covenants set forth below,

 

(a)        
Non-Competition. In consideration of the promises contained herein and the Consideration set forth in Paragraph 3, without
the prior written consent of the Company, you shall not, at any time during the period commencing on the Execution Date and terminating
on the three (3) year anniversary date of the Execution Date, (i) directly or indirectly engage in, represent in any way, be connected
with, or otherwise render any services to any Competing Business (as hereinafter defined) competing with the business of the Company or
any direct or indirect subsidiary or affiliate thereof in the United States, whether such engagement shall be as an officer, director,
owner, employee, partner, affiliate or other participant in any Competing Business, or (ii) assist others in engaging in any Competing
Business in the manner described in clause (i) above. As used herein, “Competing Business” shall mean any firm or business
organization that competes (i) with the Company in the development and/or commercialization of data-driven technology and solutions (including,
but not limited to, risk adjustment services, pharmacy benefit management solutions, cloud-based electronic health records solutions,
and third-party administration services) or pharmacy services (including, but not limited to, medication fulfillment and adherence packaging
services) to the types of entities now served or proposed to be served by the Company or (ii) in a business area discussed in writing
by the Company before the Termination Date for entry within twelve (12) months of Termination Date. Notwithstanding the foregoing restrictions,
it shall not be a violation of this Paragraph 7(a) for you to own a five (5%) percent or smaller interest in any corporation required
to file periodic reports with the United States Securities and Exchange Commission, so long as you perform no services or lend any assistance
to such corporation.

 

(b)        
Non-Solicitation. In consideration of the promises contained herein and the Consideration set forth in Paragraph 3, without
the prior written consent of the Company, you shall not, at any time during the period commencing on the Execution Date and terminating
on the three (3) year anniversary date of the Execution Date, directly or indirectly, (i) induce or solicit any employees of the
Company or any direct or indirect subsidiary or affiliate thereof to terminate their employment with the Company or any such direct or
indirect subsidiary or affiliate or to engage in any Competing Business; (ii) hire any employee of the Company or any direct or indirect
subsidiary or affiliate thereof or any person who was employed by the Company in the 12 month period prior to the hiring; or (iii) induce
any entity or person with which the Company or any direct or indirect subsidiary or any affiliate thereof has a business relationship
to terminate or alter such business relationship.

 

(c)        
You understand that the foregoing restrictions may limit your ability to earn a livelihood in a business similar to the business
of the Company or any subsidiary or affiliate thereof, but you nevertheless believes that you have received sufficient consideration and
other benefit to justify clearly such restrictions which, in any event (given your education, skills and ability), you do not believe
would prevent you from earning a living.

 

    4

     

    

 

(d)        
If the duration of, the scope of or any business activity covered by any provision of this Section 7 is in excess of what is determined
to be valid and enforceable under applicable law, such provision shall be construed to cover only that duration, scope or activity that
is determined to be valid and enforceable. You hereby acknowledge that this Section 7 shall be given the construction that renders its
provisions valid and enforceable to the maximum extent, not exceeding its express terms, possible under applicable law.

 

(e)        
Non-Disparagement.  During the period commencing on the Execution Date and terminating on the five (5) year anniversary
date of the Execution Date, you shall not disparage the Company or their respective officers, directors, investors, employees, and affiliates
or make any public statement reflecting negatively on the Company or their respective officers, directors, investors, employees, and affiliates,
including (without limitation) any matters relating to the operation or management of the Company, irrespective of the truthfulness or
falsity of such statement. The Company shall instruct and take all reasonable steps to cause its Named Executive Officers (as defined
under Item 402 of Regulation S-K) and members of the Board not to, disparage the Executive on any matters relating to the Executive’s
services to the Company, business, professional or personal reputation or standing in the pharmacy industry, irrespective of the truthfulness
or falsity of such statement. Nothing in this section shall prohibit the Parties from testifying truthfully in any forum or to any governmental
agency.

 

(f)        
Proprietary Information.  During the period commencing on the Execution Date and terminating on the three (3) year
anniversary date of the Execution Date, you shall hold in strictest confidence and will not disclose, use, lecture upon or publish any
Proprietary Information (defined below) of the Company, unless the Company expressly authorizes such disclosure in writing or it is required
by law or in a judicial or administrative proceeding in which event you shall promptly notify the Company of the required disclosure and
assist the Company if a determination is made to resist the disclosure.  For purposes of this Paragraph 7(e), “Proprietary
Information” shall mean any and all confidential and/or proprietary knowledge, data or information of the Company or its respective
affiliated entities, including (without limitation) any information relating to financial matters, investments, budgets, business plans,
marketing plans, personnel matters, business contacts, products, processes, know-how, designs, methods, improvements, discoveries, inventions,
ideas, data, programs, and other works of authorship; provided, that it shall not include any information that is known to the Company
to be publicly available.

 

(e) Invention Assignment. 
All inventions, innovations, improvements, developments, methods, designs, analyses, reports, and all similar or related information which
relates to either the Company’s actual or anticipated business, research and development or existing or future products or services
and which were conceived, developed or made by you while you were employed by the Company (the “Work Product”) belong to the
Company and not you.  You shall promptly disclose such Work Product to the Board of Directors of the Company, and, for the period
commencing on the Execution Date and terminating on the three (3) year anniversary date of the Execution Date, perform all actions reasonably
requested by the applicable Board of Directors to establish and confirm such ownership (including, without limitation, assignments, consents,
powers of attorneys and other instruments).

 

(f)  Return of Property. 
On or before the Termination Date, you will deliver to the person designated by the Company all originals and copies of all documents
and property of the Company in your possession, under your control or to which you may have access.  You will not reproduce or appropriate
for your own use, or for the use of others, any property, Proprietary Information or Work Product.

 

8.         
Withholding: All payments under this Agreement are subject to applicable tax withholding.

 

9.         
Compliance with Section 409A of the Code. This Agreement is intended to comply with the requirements of section 409A of
the Code or an exception, and shall be administered accordingly. Notwithstanding anything in the Agreement to the contrary, distributions
may only be made under the Agreement upon an event and in a manner permitted by section 409A to the extent applicable. Payments to be
made upon termination of employment under this Agreement may only be made upon a “separation from service” under section 409A.
For purposes of section 409A, each payment shall be treated as a separate payment. In no event may you, directly or indirectly, designate
the calendar year of a payment.

 

    5

     

    

 

10.        
Governing Law. This Agreement will be governed by and construed in accordance with the laws of the State of New Jersey.

 

11.        
Entire Agreement. This Agreement constitute the entire agreement between the parties relating to the matters contained herein
and supersedes any and all prior representations, agreements, written or oral, expressed or implied.

 

12.        
Severability. In the event a court, arbitrator, or other entity with jurisdiction determines that any portion of this Agreement
(other than the general release clause) is invalid or unenforceable, the remaining portions of the Agreement shall remain in full force
and effect.

 

13.        Headings;
Days. Headings contained in this Agreement are for convenience of reference only and are not intended, and shall not be construed,
to modify, define, limit, or expand the intent of the parties as expressed in this Agreement, and they shall not affect the meaning or
interpretation of this Agreement. All references to a number of days throughout this Agreement refer to calendar days.

 

14.        Representations.
You agree and represent that (a) you have read carefully the terms of this Agreement, including the general release; (b) you have had
an opportunity to and have been advised by the Company to review this Agreement, including the general release, with an attorney; (c)
you understand the meaning and effect of the terms of this Agreement, including the general release; (d) you were given twenty-one (21)
days to determine whether you wished to sign this Agreement, including the general release; (e) your decision to sign this Agreement,
including the general release, is of your own free and voluntary act without compulsion of any kind; (f) no promise or inducement not
expressed in this Agreement has been made to you; and (g) you have adequate information to make a knowing and voluntary waiver.

 

15.        
Revocation Period. If you sign this Agreement, you will retain the right to revoke it for seven (7) days (“Revocation
Period”). If you revoke this Agreement, you are indicating that you have changed your mind and do not want to be legally bound
by this Agreement. This Agreement shall not be effective until after the Revocation Period has expired without your having revoked it.
To revoke this Agreement, you must send a letter to the attention of the General Counsel of the Company. The letter must be received within
seven (7) days of your execution of this Agreement. If the seventh day is a Sunday or federal holiday, then the letter must be received
by the following business day. If you revoke this Agreement on a timely basis, you shall not be eligible for the Consideration set forth
in Paragraph 3 above.

 

16.        
Expiration Date. As noted above, you have twenty-one (21) days to decide whether you wish to sign this Agreement. If you
do not sign this Agreement on or before that time, then this Agreement is withdrawn and you will not be eligible for the Consideration
set forth in Paragraph 3 above.

 

[Signature Page Follows]

 

    6

     

    

 

IN WITNESS WHEREOF, and intending
to be legally bound hereby, you and the Company hereby execute the foregoing Executive Transition and Separation Agreement as of the Execution
Date set forth below.

 

	Dr. Orsula V. Knowlton	 	Tabula Rasa Healthcare, Inc.
	/s/ Orsula V. Knowlton	 	/s/ Brian W. Adams
	Execution Date:	September 13, 2022	 	By:	Brian W. Adams
	 	 	Title:	Interim Chief Executive Officer
	 	 	Date:	September 13, 2022

 

    7Exhibit 10.4

 

CONSULTING SERVICES AGREEMENT

 

This
CONSULTING SERVICES AGREEMENT (this “Agreement”), is made as of this 13th day of September, 2022 (“Effective
Date”), by and between Dr. Calvin H. Knowlton (“Consultant”) and Tabula Rasa Healthcare, Inc. (“Company”).

 

W I T N E S S E T H:

 

WHEREAS, Consultant previously
served as the Chief Executive Officer of Company (“CEO”) of Company;

 

WHEREAS,
Consultant has terminated employment as the CEO pursuant to the terms and conditions of the Executive Transition and Separation
Agreement, effective September 13, 2022 (the “Separation Agreement”) and
Company wishes to retain Consultant to continue to provide certain consulting and advisory services as set forth in Paragraph 1 below;
and

 

WHEREAS, Consultant has agreed
to provide the consulting and advisory services on the terms and conditions set forth in this Agreement.

 

NOW, THEREFORE, in consideration
of the promises and of the mutual representations, warranties and agreements set forth herein, Consultant and Company agree as follows:

 

1.         
Services. During the Term (as defined in Paragraph 4 below), Consultant shall provide consulting and advisory services to
Company’s Board of Directors and interim Chief Executive Officer on an as needed basis at the direction of Company’s Board
of Directors, including assisting with the transition of key client relationships and strategic business partners and prospects (the “Services”).
Consultant agrees to use reasonable best efforts in connection with performing the Services under this Agreement.

 

2.         
Compensation. In exchange for the Services, Consultant shall be paid an hourly rate of $265.00 per hour, payable monthly
in installments, over the Term.

 

3.         
Term and Termination. This Agreement shall commence on the Effective Date and shall automatically terminate on December
31, 2022 (the “Term”); provided, that, this Agreement may be extended by mutual agreement of the parties and may be terminable
by either party for any reason or no reason upon thirty (30) days advance written notice. The effective date of the termination set forth
in the written notice will be the “Termination Date.”

 

4.         
No Benefits; Taxes.

 

(a)       
Consultant is not an employee of Company and will not be entitled to participate in, or receive any, benefit or right as a Company
employee under any Company employee benefit and welfare plans, including, without limitation, employee insurance, pension, savings and
security plans, as a result of entering into this Agreement.

 

     

     

    

 

(b)       
Consultant shall be responsible for all estimated, withholding, social security, disability, unemployment, self-employment and
other taxes, imposed on Consultant by the federal government or any other domestic or non-domestic, federal, state, or local tax authority.

 

(c)       
Company shall reimburse Consultant for reasonable expenses associated with rendering the Services; provided, however, that Consultant
is not authorized to incur any expenses on behalf of Company without prior written consent of the Company’s Board of Directors,
and all statements submitted by Consultant for services and expenses shall be in the form prescribed by Company and shall be accompanied
by receipts for all expenses.

 

5.         
Restrictive Covenant Obligations. Consultant acknowledges and agrees that Consultant is bound by the restrictive covenants
set forth in the Separation Agreement.

 

6.         
Delivery of Records. Upon the Termination Date, Consultant shall deliver to Company all correspondence, reports, keys, ID
badge, records and any and all other documents pertaining to or containing information relative to the business of Company, and Consultant
shall not remove any of such records either during the Term or upon the Termination Date.

 

7.         
No Agency Relationship. This Agreement does not, and shall not be deemed to, make either party hereto the agent or legal
representative of the other for any purpose whatsoever. Neither party shall have the right or authority to assume or create any obligations
or responsibility whatsoever, express or implied, on behalf of or in the name of the other, or to bind the other in any respect whatsoever.

 

8.         
Independent Contractor. In making and performing this Agreement, Consultant shall act at all times as an independent contractor
and nothing contained in this Agreement shall be construed or implied to create between Consultant and Company an agency, partnership,
or employee-employer relationship, or to create between Consultant and Company any other form of legal association or arrangement which
imposes liability upon one party for the act or failure to act of the other party.

 

9.         
Assignment. This Agreement shall be binding upon the parties hereto, the heirs, and legal representatives of Consultant
and the successors and assigns of Company. The Consultant may not assign or otherwise transfer any of Consultant’s rights or obligations
under this Agreement without the prior written consent of Company.

 

10.       
Notices. Any notice required, permitted or intended to be given under this Agreement shall be in writing and shall be deemed
to have been given only if delivered personally or sent by registered or certified mail, return receipt requested, postage prepaid to
the appropriate address shown below, or such revised address as is delivered to the other party by the same means.

 

(a)       
Notices to Company shall be addressed to Company in care of the Chairman of the Board of Directors at the corporate headquarters
of Company.

 

(b)       
Notices to Consultant shall be sent to the most recent address on file with Company.

 

    2

     

    

 

11.        Entire
Agreement. This Agreement and the Separation Agreement constitute the entire agreement between the parties in connection with the
subject matter hereof, supersedes any and all prior agreements or understandings between the parties and may only be changed by agreement
in writing between the parties.

 

12.        Construction. This Agreement shall be construed and enforced in accordance with the laws of the State of New Jersey, without
application of the principles of conflicts of laws.

 

13.        Counterparts; Facsimile Signatures. This Agreement may be executed in multiple counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. Facsimile signatures shall be considered original
signatures.

 

14.        Severability. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction,
this Agreement shall be interpreted and enforceable as if such provision were severed or limited, but only to the extent necessary to
render such provision and this Agreement enforceable.

 

[SIGNATURE PAGE FOLLOWS]

 

    3

     

    

 

IN WITNESS WHEREOF, and intending
to be legally bound, the parties have executed this Agreement the day and year first above written.

 

	 	Tabula Rasa Healthcare, Inc.
	 	 
	 	By:	/s/ Brian W. Adams
	 	 	Name: Brian W. Adams
	 	 	Title: Interim Chief Executive Officer
	 	 
	 	Dr. Calvin H. Knowlton
	 	 
	 	/s/ Calvin H. Knowlton

 

    4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]